News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
795,721 Results
Type
Article (76898)
Company Profile (466)
Press Release (718357)
Multimedia
Podcasts (124)
Webinars (14)
Section
Business (219748)
Career Advice (3114)
Deals (37800)
Drug Delivery (129)
Drug Development (89241)
Employer Resources (182)
FDA (17657)
Job Trends (16650)
News (376377)
Policy (37431)
Tag
Academia (2989)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (55567)
ALS (99)
Alzheimer's disease (1501)
Antibody-drug conjugate (ADC) (155)
Approvals (17624)
Artificial intelligence (304)
Autoimmune disease (28)
Automation (16)
Bankruptcy (376)
Best Places to Work (12550)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (309)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (300)
Cancer (2427)
Cardiovascular disease (204)
Career advice (2638)
Career pathing (34)
CAR-T (173)
Cell therapy (484)
Cervical cancer (21)
Clinical research (72075)
Collaboration (910)
Company closure (1)
Compensation (546)
Complete response letters (30)
COVID-19 (2862)
CRISPR (48)
C-suite (264)
Cystic fibrosis (107)
Data (2266)
Decentralized trials (2)
Denatured (44)
Depression (55)
Diabetes (296)
Diagnostics (6870)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (136)
Drug pricing (126)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (88475)
Editorial (45)
Employer branding (23)
Employer resources (160)
Events (124124)
Executive appointments (772)
FDA (18978)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (807)
Gene editing (119)
Generative AI (30)
Gene therapy (354)
GLP-1 (847)
Government (5070)
Grass and pollen (6)
Guidances (67)
Healthcare (20762)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (144)
Indications (30)
Infectious disease (3022)
Inflammatory bowel disease (153)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (101)
Interviews (571)
IPO (17330)
IRA (51)
Job creations (4574)
Job search strategy (2200)
Kidney cancer (11)
Labor market (35)
Layoffs (548)
Leadership (24)
Legal (9406)
Liver cancer (81)
Lung cancer (345)
Lymphoma (159)
Machine learning (7)
Management (63)
Manufacturing (347)
MASH (75)
Medical device (14486)
Medtech (14491)
Mergers & acquisitions (21031)
Metabolic disorders (787)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2107)
NextGen: Class of 2025 (7452)
Non-profit (5046)
Now hiring (34)
Obesity (425)
Opinion (274)
Ovarian cancer (78)
Pain (99)
Pancreatic cancer (86)
Parkinson's disease (161)
Partnered (24)
Patents (250)
Patient recruitment (116)
Peanut (51)
People (62640)
Pharmaceutical (115)
Pharmacy benefit managers (21)
Phase I (22248)
Phase II (31410)
Phase III (23655)
Pipeline (1254)
Policy (170)
Postmarket research (3349)
Preclinical (9868)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (430)
Real estate (6901)
Recruiting (72)
Regulatory (25263)
Reports (45)
Research institute (2643)
Resumes & cover letters (479)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (142)
Series B (91)
Service/supplier (17)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4073)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (46)
The Weekly (78)
Vaccines (809)
Venture capitalists (43)
Weight loss (303)
Women's health (39)
Worklife (20)
Date
Today (150)
Last 7 days (949)
Last 30 days (2778)
Last 365 days (35030)
2025 (11506)
2024 (37605)
2023 (42441)
2022 (53826)
2021 (58597)
2020 (57480)
2019 (50984)
2018 (38820)
2017 (36180)
2016 (36725)
2015 (42837)
2014 (36911)
2013 (33296)
2012 (34834)
2011 (34800)
2010 (34335)
Location
Africa (1105)
Alabama (60)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (47428)
Australia (8215)
California (6368)
Canada (2049)
China (563)
Colorado (282)
Connecticut (300)
Delaware (156)
Europe (107857)
Florida (941)
Georgia (215)
Idaho (62)
Illinois (608)
India (29)
Indiana (328)
Iowa (10)
Japan (169)
Kansas (109)
Kentucky (27)
Louisiana (12)
Maine (69)
Maryland (956)
Massachusetts (4886)
Michigan (245)
Minnesota (415)
Mississippi (2)
Missouri (88)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (70)
New Jersey (1810)
New Mexico (31)
New York (1812)
North Carolina (1103)
North Dakota (9)
Northern California (2747)
Ohio (217)
Oklahoma (15)
Oregon (42)
Pennsylvania (1416)
Puerto Rico (13)
Rhode Island (33)
South America (1492)
South Carolina (24)
South Dakota (1)
Southern California (2367)
Tennessee (104)
Texas (946)
United States (24449)
Utah (191)
Virginia (166)
Washington D.C. (68)
Washington State (592)
West Virginia (3)
Wisconsin (66)
795,721 Results for "johnson and johnson pharmaceutical research and development llc pa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
9 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
11 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
April 28, 2025
·
10 min read
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
April 7, 2025
·
14 min read
Press Releases
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
April 25, 2025
·
14 min read
Press Releases
Johnson & Johnson Reports Q1 2025 Results
April 15, 2025
·
23 min read
Press Releases
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
March 12, 2025
·
8 min read
Press Releases
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
April 21, 2025
·
10 min read
Press Releases
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
April 28, 2025
·
1 min read
Press Releases
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
April 7, 2025
·
1 min read
1 of 79,573
Next
